Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 18;18(16):6129–6144. doi: 10.7150/ijbs.74951

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

The REV-ERBα antagonist SR8278 exhibited therapeutic effects against HCC in vitro and in vivo. (A and B) MTS and colony formation assays were conducted for MHCC97H and Hep3B cells treated with 20 µM SR8278 for 24 h. (C and D) Scratch-wound-healing and matrigel invasion assays for SR8278-treated MHCC97H and Hep3B cells. (E) Subcutaneous tumor-growth curves for SR8278-treated MHCC97H cells (n=6 mice/group). (F) Dissected subcutaneous tumors (left panel) and their weights (right panel) (n=6 mice/group). (G) The number of lung metastasis nodules in each group (n=6 mice/group). Scale bar, 100 µm. *p <0.05.